Early use of Xeomin neurotoxin for local anti-spasticity therapy for pes equines after acquired brain injury (ABI)

References

• Hesse S. Botulinum toxin A in the treatment of spasticity after stroke. Aktuelle Neurologie 2000; 27: 412
   Web of Science ®Google Scholar
• Sheean G. Botulinum toxin should be first-line treatment for post-stroke spasticity. Journal of Neurology, Neurosurgery & Psychiatry 2009; 80: 359–361
   PubMed Web of Science ®Google Scholar
• Ziegler K. Treatment of spasticity–A physiotherapeutic approach. Psychoneurologie 2008; 34: 30–35
   Google Scholar
• Dietz V, Sinkjaer T. Spastic movement disorder: Impaired reflex function and altered muscle mechanics. Lancet Neurology 2007; 6: 725–733
   PubMed Web of Science ®Google Scholar
• Marshall S, Teasell R, Bayona N, Lippert C, Chundamala J, Villamere J, Mackie D, Cullen N, Bayley M. Motor impairment rehabilitation post acquired brain injury. Brain Injury 2007; 21: 133–160
   PubMed Web of Science ®Google Scholar
• Pohl M, Mehrholz J, Rockstroh G, Rückriem S, Koch R. Contractures and involuntary muscle over-activity in severe brain injury. Brain Injury 2007; 21: 421–432
   PubMed Web of Science ®Google Scholar
• Ansari NN, Adelmanesh F, Naghdi S, Tabtabaei A. The effect of physiotherapeutic ultrasound on muscle spasticity in patients with hemiplegia: A pilot study. Electromyography Clinical & Neurophysiology 2006; 46: 247–252
   PubMedGoogle Scholar
• Mehrholz J, Major Y, Meissner D, Sandi-Gahun S, Koch R, Pohl M. The influence of contractures and variation in measurement stretching velocity on the reliability of the Modified Ashworth Scale in patients with severe brain injury. Clinical Rehabilitation 2005; 19: 63–72
   PubMed Web of Science ®Google Scholar
• Tafti MA, Cramer SC, Gupta R. Orthopaedic management of the upper extremity of stroke patients. Journal of the American Academy of Orthopaedic Surgeons 2008; 16: 462–470
   PubMed Web of Science ®Google Scholar
• Dressler D. Routine use of Xeomin in patients previously treated with Botox: Long term results. European Journal of Neurology: The official journal of the European Federation of Neurological Societies 2009; 16: 2–5
   PubMed Web of Science ®Google Scholar
• Kanovský P, Slawek J, Denes Z, Platz T, Sassin I, Comes G, Grafe S. Efficacy and safety of botulinum neurotoxin NT 201 in poststroke upper limb spasticity. Clinical Neuropharmacology 2009; 32: 259–265
   PubMed Web of Science ®Google Scholar
• Camargo CH, Teive HA, Zonta M, Silva GC, Oliveira MR, Roriz MM, Brandi IV, Becker N, Scola RH, Werneck LC. Botulinum toxin type A in the treatment of lower-limb spasticity in children with cerebral palsy. Arquivos de Neuro-Psiquiatria 2009; 67: 62–68
   PubMed Web of Science ®Google Scholar
• AutorNey JP, Joseph KR. Neurologic uses of botulinum neurotoxin type A. KörperschaftMadigan Army Medical Center, neurology service, Tacoma, WA, USA. QuelleNeuropsychiatric disease and treatment erscheinungsjahr 2007. Erscheinungsdatum 2007; 3: 785–798
   Google Scholar
• Mukai Y, Kaji R. Use of botulinum neurotoxin for spasticity. Brain and Nerve 2008; 60: 1421–1426
   PubMedGoogle Scholar
• Dai A, Wasay M, Awan S. Botulinum toxin type A with oral baclofen versus oral tizanidine: A nonrandomized pilot comparison in patients with cerebral palsy and spastic equinus foot deformity. Journal of Child Neurology 2008; 23: 1464–1466
   PubMed Web of Science ®Google Scholar
• Simpson DM, Gracies JM, Yablon SA, Barbano R, Brashear A. Botulinum neurotoxin versus tizanidine in upper limb spasticity: A placebo-controlled study. Journal of Neurology, Neurosurgery & Psychiatry 2009; 80: 380–385
   PubMed Web of Science ®Google Scholar
• Wissel J. Fokale therapie der spastizität im multi-professionellen team. Der Nervenarzt 2008; 79: 24–28
   PubMed Web of Science ®Google Scholar
• Baricich A, Carda S, Bertoni M, Maderna L, Cisari C. A single-blinded, randomized pilot study of botulinum toxin type A combined with non-pharmacological treatment for spastic foot. Journal of Rehabilitation Medicine 2008; 40: 870–872
   PubMed Web of Science ®Google Scholar
• Farina S, Migliorini C, Gandolfi M, Bertolasi L, Casarotto M, Manganotti P, Fiaschi A, Smania N. Combined effects of botulinum toxin and casting treatments on lower limb spasticity after stroke. Functional Neurology 2008; 23: 87–91
   PubMed Web of Science ®Google Scholar
• Simpson DM, Gracies JM, Graham HK, Miyasaki JMNaumann MRussman B, Simpson LL, So Y. Assessment: Botulinum neurotoxin for the treatment of spasticity (an evidence-based review): Report of the therapeutics and technology assessment Subcommittee of the American Academy of Neurology. Neurology 2008; 7: 1691–1698
   Google Scholar
• Jankovic J. Clinical efficacy and tolerability of Xeomin in the treatment of blepharospasm. European Journal of Neurology: The official journal of the European Federation of Neurological Societies 2009; 16: 14–18
   PubMed Web of Science ®Google Scholar
• Frevert J. Xeomin is free from complexing proteins. Toxicon: Official journal of the International Society on Toxinology 2009; 54: 697–701
   PubMed Web of Science ®Google Scholar
• Frevert J. Xeomin: An innovative new botulinum toxin type A. European Journal of Neurology: The official journal of the European Federation of Neurological Societies 2009; 16: 11–13
   PubMed Web of Science ®Google Scholar
• Jos WH, Blümel J, Grafe S. Botulinum neurotoxin type A free of complexing proteins (XEOMIN) in focal dystonia. Drugs 2007; 67: 669–683
   PubMed Web of Science ®Google Scholar
• Jankovic J, Kenney C, Grafe S, Goertelmeyer R, Comes G. Relationship between various clinical outcome assessments in patients with blepharospasm. Movement Disorders: Official journal of the Movement Disorder Society 2009; 24: 407–413
   PubMed Web of Science ®Google Scholar
• Hesse S, Werner C, Bardeleben A. Lokomotionstherapie chronisch hemiparetischer patienten nach therapie eines spastischen spitzfußes mit hochgereinigtem botulinumtoxin A (Xeomin®). Neurology & Rehabilitation 2007; 13: 327
   Google Scholar
• Bhidayasiri R, Cardoso F, Truong DD. Botulinum toxin in blepharospasm and oromandibular dystonia: Comparing different botulinum toxin preparations. European Journal of Neurology: The official journal of the European Federation of Neurological Societies 2006; 13: 21–29
   PubMed Web of Science ®Google Scholar
• Wissel J, Ward AB, Erztgaard P, Bensmail D, Hecht MJ, Lejeune TM, Schnider P, Altavista MC, Cavazza S, Deltombe T. European consensus table on the use of botulinum toxin type A in adult spasticity. Journal of Rehabilitation Medicine 2009; 41: 13–25
   PubMed Web of Science ®Google Scholar